title: Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
authors.forename: Míriam
authors.initials: M
authors.lastname: Mañosa
authors.forename: Eugeni
authors.initials: E
authors.lastname: Domènech
authors.forename: Laura
authors.initials: L
authors.lastname: Marín
authors.forename: Alejandro
authors.initials: A
authors.lastname: Olivé
authors.forename: Yamile
authors.initials: Y
authors.lastname: Zabana
authors.forename: Eduard
authors.initials: E
authors.lastname: Cabré
authors.forename: Miquel A
authors.initials: MA
authors.lastname: Gassull
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab